Gatti, Milo http://orcid.org/0000-0003-3018-3779
Pea, Federico http://orcid.org/0000-0002-6966-7167
Funding for this research was provided by:
Alma Mater Studiorum - UniversitĂ di Bologna
Article History
Accepted: 14 August 2022
First Online: 5 September 2022
Declarations
:
: Open access funding provided by Alma Mater Studiorum - UniversitĂ di Bologna within the CRUI-CARE Agreement.
: Milo Gatti reports grants from Angelini. Federico Pea participated in a speaker bureau for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Pfizer, and Sanofi Aventis, and in an advisory board for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfizer, Shionogi, and Thermo-Fisher.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MG and FP made substantial contributions to the conception of the manuscript. MG was involved in drafting the manuscript. FP made substantial contributions in revising the manuscript critically for important intellectual content. All authors approved the final version of the manuscript.